Core Insights - Samsung Biologics has announced the acquisition of 100% of Human Genome Sciences from GSK for USD 280 million, marking its first U.S.-based manufacturing site and expanding its global footprint [1][3][7] - The Rockville facility includes two cGMP manufacturing plants with a combined capacity of 60,000 liters, supporting both clinical and commercial production [2][3] - The acquisition will retain over 500 employees at the site, ensuring operational continuity and stability [3] Company Expansion - The acquisition is part of Samsung Biologics' strategy to enhance its manufacturing capabilities in the U.S. and deepen collaboration with local stakeholders [5][7] - The company plans to invest further in the Rockville site to expand its capacity and upgrade technology, contributing to a more resilient U.S. supply chain for critical biologic medicines [2][7] - Samsung Biologics has a proven track record of operational excellence, with significant capacity across its Bio Campus I and II, totaling 785,000 liters [4][8] Industry Context - GSK's divestment of the Rockville site is aimed at securing the manufacture of important medicines on U.S. soil, aligning with its commitment to invest USD 30 billion in R&D and manufacturing in the U.S. over the next five years [6] - The acquisition underscores the long-term dedication of Samsung Biologics to the U.S. biopharmaceutical industry and supply chain [7]